{"id":950086,"date":"2026-04-09T06:04:08","date_gmt":"2026-04-09T10:04:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\/"},"modified":"2026-04-09T06:04:08","modified_gmt":"2026-04-09T10:04:08","slug":"zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\/","title":{"rendered":"Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>\u2022 Adam Schayowitz, Ph.D., MBA appointed as Head of R&amp;D<br \/><\/em><br \/>\n        <em>\u2022 Scott Platshon appointed as Chief Business Officer\u00a0<\/em>\n      <\/p>\n<p>VANCOUVER, British Columbia, April  09, 2026  (GLOBE NEWSWIRE) &#8212; Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the full-time appointments of Dr. Adam Schayowitz and Mr. Scott Platshon as of April 9, 2026, from their previously interim roles. Both Dr. Schayowitz and Mr. Platshon will report directly to Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks.<\/p>\n<p>\u201cThese appointments come at a pivotal time for Zymeworks as we enter a year focused on execution across our pipeline, partnerships, and broader corporate strategy,\u201d said Galbraith. \u201cAdam\u2019s deep oncology and R&amp;D expertise will accelerate our clinical development and unlock additional value, while Scott\u2019s investment acumen and strategic vision will be instrumental in helping to expand our asset portfolio and drive long-term returns. Together with the recent appointment of Ms. Kristin Stafford as Chief Financial Officer, these leadership additions better position Zymeworks to execute on its strategy and deliver sustained value for patients and shareholders.\u201d<\/p>\n<p>Dr. Schayowitz has been appointed as Executive Vice President and Head of Research &amp; Development. He will work closely with Zymeworks\u2019 R&amp;D and Business Development teams to advance the Company\u2019s portfolio of product candidates, while supporting its strategy to integrate partnerships and collaborations into its wholly-owned R&amp;D pipeline. With nearly two decades of experience in oncology drug development, Dr. Schayowitz will play a key role in advancing programs in areas of high unmet need and preparing additional product candidates for progression into clinical studies.<\/p>\n<p>Mr. Platshon will serve as Executive Vice President and Chief Business Officer and continue to lead Zymeworks\u2019 asset aggregation strategy while managing expected future cash flows from Ziihera\u00ae (zanidatamab-hrii) and other licensed healthcare assets, including pasritamig, which is being advanced into Phase 3 registration studies by Johnson &amp; Johnson Innovative Medicine. In his full-time role as Chief Business Officer, he is responsible for executing Zymeworks\u2019 strategy to build and actively manage a diversified portfolio of revenue-generating assets to help drive long-term shareholder value.<\/p>\n<p>Dr. Schayowitz and Mr. Platshon both join the executive leadership team from EcoR1 Capital, a significant shareholder in Zymeworks.<\/p>\n<p>Recent milestones, including the Phase 1 study initiation for ZW251 and expanding global approvals of zanidatamab, underscore Zymeworks\u2019 continued momentum across its development pipeline and strategic partnerships. The Company remains focused on disciplined execution while advancing a differentiated strategy that integrates R&amp;D innovation with strategic collaborations.<\/p>\n<p>Building on this progress, Zymeworks is advancing a diversified portfolio of revenue-generating assets supported by its asset aggregation strategy. Positive Phase 3 HERIZON-GEA-01 data for zanidatamab further strengthens the Company\u2019s position to drive long-term value through a balanced approach that combines internal pipeline advancement with active management and expansion of its royalty and licensed asset portfolio. This integrated model is designed to optimize future cash flows while supporting continued investment in innovative therapeutics.<\/p>\n<p>\n        <strong>About Zymeworks Inc. <\/strong>\n      <\/p>\n<p>Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. Zymeworks\u2019 asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera\u00ae (zanidatamab-hrii) and other licensed products and product candidates, such as pasritamig. In addition, Zymeworks is also building a portfolio of healthcare assets that can generate strong cash flows, while supporting the development of innovative medicines. Zymeworks engineered and developed Ziihera, a HER2-targeted bispecific antibody using the Zymeworks\u2019 proprietary Azymetric\u2122 technology and has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Zymeworks\u2019 complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.<\/p>\n<p>\n        <strong>Cautionary Note Regarding Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This press release includes \u201cforward-looking statements\u201d or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to Zymeworks\u2019 expectations regarding implementation of its strategic priorities and long-term strategy to maximize value creation; the expected contributions of personnel to Zymeworks\u2019 clinical development, strategic goals and long-term shareholder value for patients and shareholders; the anticipated benefits of strategic partnerships; Zymeworks\u2019 and its partners\u2019 clinical development and advancement of product candidates; future regulatory filings and approvals; the commercial potential of technology platforms and product candidates; and other information that is not historical information. When used herein, words such as \u201cplan\u201d, \u201cbelieve\u201d, \u201cexpect\u201d, \u201cmay\u201d, \u201ccontinue\u201d, \u201canticipate\u201d, \u201cpotential\u201d, \u201cwill\u201d, \u201con track\u201d, \u201cprogress\u201d, \u201cpreserve\u201d, \u201cintend\u201d, \u201ccould\u201d, \u201cposition\u201d and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks\u2019 current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: any of Zymeworks\u2019 or its partners\u2019 product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; Zymeworks may not achieve milestones or receive additional payments or royalties under its collaborations; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions, including the impact of tariffs; potential negative impacts of FDA regulatory delays and uncertainty around recent policy developments, changes in the leadership of federal agencies such as the FDA, staff layoffs, budget cuts to agency programs and research, and changes in drug pricing controls; the impact of global and regional geopolitical or public health developments on Zymeworks\u2019 business, research and clinical development plans and timelines and results of operations; zanidatamab may not be successfully commercialized; Zymeworks\u2019 business strategy related to anticipated and potential future milestones and royalty streams and existing and potential new partnerships may not be successfully implemented; Zymeworks\u2019 evolution of its business strategy may not deliver meaningful shareholder returns; Zymeworks may be unsuccessful in actively managing and\/or aggregating revenue-generating assets alongside its active R&amp;D operations; ongoing and future clinical trials may not demonstrate safety and efficacy of any of Zymeworks\u2019 or its collaborators\u2019 product candidates; data providing early validation of our antibody drug conjugate platform and next generation pipeline programs may not be replicated in future studies; Zymeworks\u2019 assumptions and estimates regarding its financial condition, future financial performance and estimated cash runway may be incorrect; inability to maintain or enter into new partnerships or strategic collaborations; and the factors described under \u201cRisk Factors\u201d in Zymeworks\u2019 quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov and www.sedarplus.ca).<\/p>\n<p>Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p>Investor Inquiries:<br \/>Shrinal Inamdar<br \/>Vice President, Investor Relations<br \/>(604) 678-1388<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sNtftT7KAo4v4t_nX4XwdpMebQTuDlQfGQelTgk_Hv22rg3usR0ZxFRqfMfVLt6Hs-Gq5Ad5XKVCfKY0qBupGwTf44gE9WgxCAvongbSlzM=\" rel=\"nofollow\" target=\"_blank\">ir@zymeworks.com<\/a>\u202f\u202f\u00a0<\/p>\n<p>Media Inquiries:<br \/>Diana Papove<br \/>Vice President, Corporate Communications<br \/>(604) 678-1388<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vHNsxAw9jCE5B2slYO-z5HSVvnJJNPaWXkam1_xWLzPbKEJfdZZW0QtkMj085iKNZj8lX0-zGvlCkE8qDtvFEFyxvzrQen6GmUpVy0U5UH0=\" rel=\"nofollow\" target=\"_blank\">media@zymeworks.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NjU5NCM3NTI2NTUwIzIyNTY4OTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OTJmMDE1MTEtNzVhNi00NDZjLWFhNGYtN2M0NmJhN2M4YmEwLTEyNjg0NDItMjAyNi0wNC0wOS1lbg==\/tiny\/Zymeworks-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u2022 Adam Schayowitz, Ph.D., MBA appointed as Head of R&amp;D \u2022 Scott Platshon appointed as Chief Business Officer\u00a0 VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) &#8212; Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the full-time appointments of Dr. Adam Schayowitz and Mr. Scott Platshon as of April 9, 2026, from their previously interim roles. Both Dr. Schayowitz and Mr. Platshon will report directly to Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. \u201cThese appointments come at a pivotal time for Zymeworks as we enter a year focused on execution across our pipeline, partnerships, and broader corporate strategy,\u201d said Galbraith. \u201cAdam\u2019s &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-950086","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u2022 Adam Schayowitz, Ph.D., MBA appointed as Head of R&amp;D \u2022 Scott Platshon appointed as Chief Business Officer\u00a0 VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) &#8212; Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the full-time appointments of Dr. Adam Schayowitz and Mr. Scott Platshon as of April 9, 2026, from their previously interim roles. Both Dr. Schayowitz and Mr. Platshon will report directly to Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. \u201cThese appointments come at a pivotal time for Zymeworks as we enter a year focused on execution across our pipeline, partnerships, and broader corporate strategy,\u201d said Galbraith. \u201cAdam\u2019s &hellip; Continue reading &quot;Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-09T10:04:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NjU5NCM3NTI2NTUwIzIyNTY4OTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth\",\"datePublished\":\"2026-04-09T10:04:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\\\/\"},\"wordCount\":1400,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NjU5NCM3NTI2NTUwIzIyNTY4OTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\\\/\",\"name\":\"Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NjU5NCM3NTI2NTUwIzIyNTY4OTM=\",\"datePublished\":\"2026-04-09T10:04:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NjU5NCM3NTI2NTUwIzIyNTY4OTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NjU5NCM3NTI2NTUwIzIyNTY4OTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\/","og_locale":"en_US","og_type":"article","og_title":"Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth - Market Newsdesk","og_description":"\u2022 Adam Schayowitz, Ph.D., MBA appointed as Head of R&amp;D \u2022 Scott Platshon appointed as Chief Business Officer\u00a0 VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) &#8212; Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the full-time appointments of Dr. Adam Schayowitz and Mr. Scott Platshon as of April 9, 2026, from their previously interim roles. Both Dr. Schayowitz and Mr. Platshon will report directly to Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. \u201cThese appointments come at a pivotal time for Zymeworks as we enter a year focused on execution across our pipeline, partnerships, and broader corporate strategy,\u201d said Galbraith. \u201cAdam\u2019s &hellip; Continue reading \"Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-09T10:04:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NjU5NCM3NTI2NTUwIzIyNTY4OTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth","datePublished":"2026-04-09T10:04:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\/"},"wordCount":1400,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NjU5NCM3NTI2NTUwIzIyNTY4OTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\/","name":"Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NjU5NCM3NTI2NTUwIzIyNTY4OTM=","datePublished":"2026-04-09T10:04:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NjU5NCM3NTI2NTUwIzIyNTY4OTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NjU5NCM3NTI2NTUwIzIyNTY4OTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/950086","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=950086"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/950086\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=950086"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=950086"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=950086"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}